中血管闭塞所致急性缺血性卒中的临床病程:静脉阿替普酶治疗与否的对比
本研究基于INTERRSeCT和PRoveIT研究数据,纳入258例中血管闭塞(MeVO)所致急性缺血性卒中患者,描述其临床病程并比较接受与未接受静脉阿替普酶治疗及是否再通的患者结局。结果显示50.0%患者获得极佳功能结局,早期再通与极佳结局显著相关,而静脉阿替普酶治疗与之无显著关联。
要点
- MeVO患者90天极佳功能结局(mRS 0-1)比例为50.0%。
- 早期再通与极佳功能结局显著相关(aOR 2.29,95%CI 1.23-4.28)。
- 静脉阿替普酶与极佳功能结局无显著关联(aOR 1.70,95%CI 0.88-3.25)。
核心结论
- 每2例MeVO患者中约有1例在最佳药物治疗下90天未达到极佳临床结局。
- 早期再通与极佳结局强烈相关,但即使接受静脉阿替普酶治疗,再通率仍低于50%。
研究设计与样本
- 汇总INTERRSeCT和PRoveIT两项研究的MeVO患者(M2/M3/A2/A3/P2/P3闭塞),共258例。
- 采用描述性统计总结基线特征和临床结局,用逻辑回归提供校正效应估计。
主要发现
- 258例MeVO患者基线NIHSS中位数为7(四分位距5-12)。
- 72.1%(186/258)接受静脉阿替普酶治疗;随访CTA显示41.8%(84/201)再通(revised arterial occlusive lesion评分2b/3)。
- 90天极佳功能结局(mRS 0-1)达50.0%(129/258),功能独立(mRS 0-2)达67.4%(174/258),死亡8.9%(23/258)。
- 未接受阿替普酶者再通率21.4%(9/42),接受者47.2%(75/159),P=0.003。
- 早期再通与极佳功能结局显著相关(aOR 2.29,95%CI 1.23-4.28),静脉阿替普酶无显著关联(aOR 1.70,95%CI 0.88-3.25)。
关键数值与推荐
- 主要结局:90天mRS 0-1(极佳功能结局)。
- 次要结局:mRS 1分偏移的common odds ratio和功能独立(mRS 0-2)。
- 再通定义:随访CTA显示revised arterial occlusive lesion评分2b/3。
临床怎么用
- MeVO患者即使接受静脉阿替普酶,再通率仍不足50%,需关注早期再通评估。
- 早期再通与极佳功能结局强烈相关,提示再通是改善预后的关键因素。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Available data on the clinical course of patients with acute ischemic stroke due to medium vessel occlusion (MeVO) are mostly limited to those with M2 segment occlusions. Outcomes are generally better compared with more proximal occlusions, but many patients will still suffer from severe morbidity. We aimed to determine the clinical course of acute ischemic stroke due to MeVO with and without intravenous alteplase treatment. METHODS: Patients with MeVO (M2/M3/A2/A3/P2/P3 occlusion) from the INTERRSeCT (The Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography) and PRoveIT (Precise and Rapid Assessment of Collaterals Using Multi-Phase CTA in the Triage of Patients With Acute Ischemic Stroke for IA Therapy) studies were included. Baseline characteristics and clinical outcomes were summarized using descriptive statistics. The primary outcome was a modified Rankin Scale score of 0 to 1 at 90 days, describing excellent functional outcome. Secondary outcomes were the common odds ratio for a 1-point shift across the modified Rankin Scale and functional independence, defined as modified Rankin Scale score of 0 to 2. We compared outcomes between patients with versus without intravenous alteplase treatment and between patients who did and did not show recanalization on follow-up computed tomography angiography. Logistic regression was used to provide adjusted effect-size estimates. RESULTS: Among 258 patients with MeVO, the median baseline National Institutes of Health Stroke Scale score was 7 (interquartile range: 5-12). A total of 72.1% (186/258) patients were treated with intravenous alteplase and in 41.8% (84/201), recanalization of the occlusion (revised arterial occlusive lesion score 2b/3) was seen on follow-up computed tomography angiography. Excellent functional outcome was achieved by 50.0% (129/258), and 67.4% (174/258) patients gained functional independence, while 8.9% (23/258) patients died within 90 days. Recanalization was observed in 21.4% (9/42) patients who were not treated with alteplase and 47.2% (75/159) patients treated with alteplase (P=0.003). Early recanalization (adjusted odds ratio, 2.29 [95% CI, 1.23-4.28]) was significantly associated with excellent functional outcome, while intravenous alteplase was not (adjusted odds ratio, 1.70 [95% CI, 0.88-3.25]). CONCLUSIONS: One of every 2 patients with MeVO did not achieve excellent clinical outcome at 90 days with best medical management. Early recanalization was strongly associated with excellent outcome but occurred in <50% of patients despite intravenous alteplase treatment.
引用
- Ospel JM, Menon BK, Demchuk AM, et al. Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment. Stroke. 2020. PMID: 33070714. doi:10.1161/STROKEAHA.120.030227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。